The information here has been written in reference to Olympias NAD+ 100mg/mL injection only
However, studies using beta-3-adrenergic receptor knockout mice revealed a more complex picture: Long-term AOD-9604 treatment failed to produce weight loss in beta-3-AR knockout mice Acute administration still increased energy expenditure and fat oxidation in knockout mice This suggests beta-3-AR expression enhancement contributes to, but does not directly mediate, lipolytic effects The peptide appears to work through an unidentified receptor mechanism that subsequently influences beta-3-adrenergic signaling pathways
These include how severe the deficiency is, how well the patient responds, and their health conditions
Ipamorelin, a growth hormone secretagogue receptor (GHSR) agonist, by contrast, appears to activate GHSR in the hypothalamus and peripheral tissues, potentially leading to the release of GH
then weekly injections in the following month, and finally monthly injections after that
